ArticleCancer cell international2020
Hsa_circ_0026416 promotes proliferation and migration in colorectal cancer via miR-346/NFIB axis.
Article in Cancer cell international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 47 citations in OpenAlex.
- CircCdh7 induces astrogliosis and neuroinflammation to trigger hypertensive effects in the rostral ventrolateral medulla.Cell & bioscience · 2025Article
- Exploring the diagnostic potential of plasma circ-CCDC66 in colorectal cancer.Scientific reports · 2025Article
- circ_0000389 inhibits intervertebral disc degeneration by targeting the miR-346/KLF7 axis.Acta biochimica et biophysica Sinica · 2025Article
- Emerging roles of CircRNA-miRNA networks in cancer development and therapeutic response.Non-coding RNA research · 2025Review
- Circular RNA microarray expression profile and potential function of circDOCK1 in colorectal cancer.Frontiers in genetics · 2025Article
- A review of circular RNAs in colorectal cancer: insights into biomarker discovery and therapeutic targeting.Frontiers in oncology · 2025Review
- CircRNAs in colorectal cancer: potential roles, clinical applications, and natural product-based regulation.Frontiers in oncology · 2025Review
- Investigating the biomarker value of circRNAs in the diagnosis of colorectal cancer: a systematic review.Discover oncology · 2024Review
- Hsa_circ_0000423 promotes colorectal cancer EMT and immune escape by competitive adsorption of miR-369-3p mediating CCND1 expression.Discover oncology · 2024Article
- Biomarker potential of competing endogenous RNA networks in Polycystic Ovary Syndrome (PCOS).Non-coding RNA research · 2024Review
- CircGAB1 Facilitates Podocyte Injury Through Sponging miR-346 and Activating MAPK6 in Diabetic Nephropathy.Applied biochemistry and biotechnology · 2024Article
- Competitive endogenous RNA networks: Decoding the role of long non-coding RNAs and circular RNAs in colorectal cancer chemoresistance.Journal of cellular and molecular medicine · 2024Review
- Downregulation of miR-182-5p by NFIB promotes NAD+ salvage synthesis in colorectal cancer by targeting NAMPT.Communications biology · 2023Article
- Circ_0004585 Facilitates Tumorigenesis of Colorectal CancerCellular and molecular bioengineering · 2023Article
- Biological functions, mechanisms, and clinical significance of circular RNA in colorectal cancer.Frontiers in oncology · 2023Review
- Review
- Review
- Circular RNA 0001666 inhibits colorectal cancer cell proliferation, invasion and stemness by inactivating the Wnt/β-catenin signaling pathway and targeting microRNA-1229.Oncology letters · 2022Article
- Long non-coding MELTF Antisense RNA 1 promotes and prognosis the progression of non-small cell lung cancer by targeting miR-1299.Bioengineered · 2022Article
- UBQLN4 is activated by C/EBPβ and exerts oncogenic effects on colorectal cancer via the Wnt/β-catenin signaling pathway.Cell death discovery · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is one of the most common cancers worldwide. Circular RNAs (circRNAs), a novel class of non-coding RNAs, have been confirmed to be key regulators of many diseases. With many scholars devoted to studying the biological function and mechanism of circRNAs, their mysterious veil is gradually being revealed. In our research, we explored a new circRNA, hsa_circ_0026416, which was identified as upregulated in CRC with the largest fold change (logFC = 3.70) of the evaluated circRNAs via analysing expression profiling data by high throughput sequencing of members of the GEO dataset (GSE77661) to explore the molecular mechanisms of CRC.
methodsqRT-PCR and western blot analysis were utilized to assess the expression of hsa_circ_0026416, miR-346 and Nuclear Factor I/B (NFIB). CCK-8 and transwell assays were utilized to examine cell proliferation, migration and invasion in vitro, respectively. A luciferase reporter assay was used to verify the combination of hsa_circ_0026416, miR-346 and NFIB. A nude mouse xenograft model was also utilized to determine the role of hsa_circ_0026416 in CRC cell growth in vivo.
resultsHsa_circ_0026416 was markedly upregulated in CRC patient tissues and plasma and was a poor prognosis in CRC patients. In addition, the area under the curve (AUC) of hsa_circ_0026416 (0.767) was greater than the AUC of CEA (0.670), CA19-9 (0.592) and CA72-4 (0.575). Functionally, hsa_circ_0026416 promotes cell proliferation, migration and invasion both in vitro and in vivo. Mechanistically, hsa_circ_0026416 may function as a ceRNA via competitively absorbing miR-346 to upregulate the expression of NFIB.
conclusionsIn summary, our findings demonstrate that hsa_circ_0026416 is an oncogene in CRC. Hsa_circ_0026416 promotes the progression of CRC via the miR-346/NFIB axis and may represent a potential biomarker for diagnosis and therapy in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.